Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

Overall number of treatment-emergent adverse events.

Time frame: Up to Day 19

Number of treatment-emergent application site reactions, by treatment.

Time frame: Up to Day 19

Change from baseline to Day 4, Day 8 and Day 12 in haematology parameters

red blood cells, white blood cells, hemoglobin, hematocrit, MCH, MMCV, MCHC, platelets, white cell differentials, measure in SI units

Time frame: Up to Day 12

Change from baseline to Day 4, Day 8 and Day 12 in clinical chemistry parameters

sodium, potassium, chloride, bicarbonate, blood urea nitrogen, glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaGT, uric acid, calcium, phosphate, albumin, triglycerides, cholesterol, lactate dehydrogenase, total protein, creatinine, total bilirubin, direct bilirubin, indirect bilirubin

Time frame: Up to Day 12

Change from baseline to Day 4, Day 8 and Day 12 in urinalysis parameters

Single parameters only to be listed if deviation from usual urine dip test, e.g., sediment, leucocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood/haemoglobin

Time frame: Up to Day 12

Number of subjects with abnormal clinical significant ECG evaluation

Evaluation of 12-lead ECG (overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant')

Time frame: Up to Day 12

Number of subjects with abnormal clinically significant findings of physical examination at Day 12.

Evaluation of physical examination (areas skin, heart, lung, abdomen, basic neurological status, general examination of eyes, ears, nose throat), overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant'